Use of nonantiarrhythmic drugs for prevention of sudden cardiac death

Journal of Cardiovascular Electrophysiology

Volumn 14, Issue 9 SUPPL., 2003, Pages

  Alberte, Cesar ^a   Zipes, Douglas P ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drugs; Sudden death; Ventricular fibrillation

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; SPIRONOLACTONE;

ASYSTOLE; CONFERENCE PAPER; DISSOCIATION; ELECTROCHEMISTRY; ELECTROPHYSIOLOGY; FIBROSIS; HEART ARREST; HEART BLOCK; HEART MUSCLE EXCITABILITY; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; ISCHEMIA; MORTALITY; PRIORITY JOURNAL; PROBABILITY; PROPHYLAXIS; SUDDEN DEATH;

EID: 0141724739     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1540-8167.14.s9.23.x     Document Type: Conference Paper

References (122)

1. Escobedo LG, Zack MM: Comparison of sudden and nonsudden coronary deaths in the United States. Circulation 1996;93:2033-2036.
2. Engelstein ZD, ed: Sudden Cardiac Death. New York, NY: McGraw-Hill, 1998.
3. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429-1435.
4. Konstam MA, Rousseau MF, Kronenberg MW, Udelson JE, Melin J, Stewart D, Dolan N, Edens TR, Ahn S, Kinan D, et al: Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation 1992;86:431-438.
5. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992;327:685-691.
6. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, et al: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-310.
7. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, et al: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-677.
8. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993;342:821-828.
9. Cleland JG, Erhardt L, Hall AS, Winter C, Ball SG: Validation of primary and secondary outcomes and classification of mode of death among patients with clinical evidence of heart failure after a myocardial infarction: A report from the Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. J Cardiovasc Pharmacol 1993;22(Suppl 9):S22-S27.
10. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC: A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333:1670-1676.
11. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet 1994;343:1115-1122.
12. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995;345:669-685.
13. Ambrosioni E, Borghi C, Magnani B: The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 1995;332:80-85.
14. Domanski MJ, Exner DV, Borkowf CB, Geller NL, Rosenberg Y, Pfeffer MA: Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. J Am Coll Cardiol 1999;33:598-604.
15. Priori SG, Aliot E, Blomstrom-Lundqvist C, Bossaert L, Breithardt G, Brugada P, Camm AJ, Cappato R, Cobbe SM, Di Mario C, Maron BJ, McKenna WJ, Pedersen AK, Ravens U, Schwartz PJ, Trusz-Gluza M, Vardas P, Wellens HJ, Zipes DP: Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 2001;22:1374-1450.
16. McKenna WJ, Haywood GA: The role of ACE inhibitors in the treatment of arrhythmias. Clin Cardiol 1990;13:VII49-VII52.
17. Gavras I: Bradykinin-mediated effects of ACE inhibition. Kidney Int 1992;42:1020-1029.
18. Rump LC, Berlit T, Schwertfeger E, Beyersdorf F, Schollmeyer P, Bohmann C: Angiotensin converting enzyme inhibition unmasks the sympathofacilitatory effect of bradykinin in human right atrium. J Hypertens 1997;15:1263-1270.
19. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Pozzi M, Morganti A, Carugo S, Mancia G: Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Circulation 1997;96:1173-1179.
20. Weber KT, Brilla CG, Campbell SE, Guarda E, Zhou G, Sriram K: Myocardial fibrosis: Role of angiotensin II and aldosterone. Basic Res Cardiol 1993;88(Suppl 1):107-124.
21. Ray SG, Pye M, Oldroyd KG, Christie J, Connelly DT, Northridge DB, Ford I. Morton JJ, Dargie HJ, Cobbe SM: Early treatment with captopril after acute myocardial infarction. Br Heart J 1993;69:215-222.
22. Pogwizd SM: Focal mechanisms underlying ventricular tachycardia during prolonged ischemic cardiomyopathy. Circulation 1994;90:1441-1458.
23. Fletcher RD, Cintron GB, Johnson G, Orndorff J, Carson P, Cohn JN: Enalapril decreases prevalence of ventricular tachycardia in patients with chronic congestive heart failure. The V-HeFT II VA Cooperative Studies Group. Circulation 1993;87:VI49-VI55.
24. Cleland JG, Shah D, Krikler S, Dritsas A, Nihoyannopoulos P, Frost G, Oakley CM: Effects of lisinopril on cardiorespiratory, neuroendocrine, and renal function in patients with asymptomatic left ventricular dysfunction. Br Heart J 1993;69:512-515.
25. Bashir Y, Sneddon JF, O'Nunain S, Paul VE, Gibson S, Ward DE, Camm AJ: Comparative electrophysiological effects of captopril or hydralazine combined with nitrate in patients with left ventricular dysfunction and inducible ventricular tachycardia. Br Heart J 1992;67:355-360.
26. Racke HF, Koppers D, Lemke P, Casaretto H, Hauswirth O: Fosinoprilat prolongs the action potential: Reduction of iK and enhancement of the L-type calcium current in guinea pig ventricular myocytes. Cardiovasc Res 1994;28:201-208.
27. Stark G, Stark U, Nagl S, Klein W, Pilger E, Tritthart HA: Acute effects of the ACE inhibitor lisinopril on cardiac electrophysiological parameters of isolated guinea pig hearts. Clin Cardiol 1991;14:579-582.
28. Ball SG, Hall AS: What to expect from ACE inhibitors after myocardial infarction. Br Heart J 1994;72:S70-S74.
29. Pitt B: Evaluation of Losartan in the Elderly (ELITE) Trial: Clinical implications. Eur Heart J 1997;18:1197-1199.
30. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - The Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-1587.
31. Dickstein K, Kjekshus J: The OPTIMMAL trial: Losartan or captopril after acute myocardial infarction. Lancet 2002;360:1885.
32. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002;359:995-1003.
33. Cohn JN, Tognoni G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-1675.
34. Cheetham C, O'Driscoll G, Stanton K, Taylor R, Green D: Losartan, an angiotensin type I receptor antagonist, improves conduit vessel endothelial function in Type II diabetes. Clin Sci (Lond) 2001;100:13-17.
35. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, Kinoshita M: Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. J Am Coll Cardiol 2000;35:714-721.
36. Goodfield NE, Newby DE, Ludlam CA, Flapan AD: Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation 1999;99:2983-2985.
37. Saito K, Gutkind JS, Saavedra JM: Angiotensin II binding sites in the conduction system of rat hearts. Am J Physiol 1987;253:H1618-H1622.
38. Kass RS, Blair ML: Effects of angiotensin II on membrane current in cardiac Purkinje fibers. J Mol Cell Cardiol 1981;13:797-809.
39. De Mello WC: Renin-angiotensin system and cell communication in the failing heart. Hypertension 1996;27:1267-1272.
40. De Mello WC, Crespo MJ: Cardiac refractoriness in rats is reduced by angiotensin II. J Cardiovasc Pharmacol 1995;25:51-56.
41. Gavras I, Gavras H: The antiarrhythmic potential of angiotensin II antagonism: Experience with losartan. Am J Hypertens 2000;13:512-517.
42. Lee YM, Peng YY, Ding YA, Yen MH: Losartan attenuates myocardial ischemia-induced ventricular arrhythmias and reperfusion injury in spontaneously hypertensive rats. Am J Hypertens 1997;10:852-858.
43. Matsuo K, Kumagai K, Annoura M, Yamanouchi Y, Handa K, Nakashima Y, Hiroki T, Arakawa K: Effects of an angiotensin II antagonist on reperfusion arrhythmias in dogs. Pacing Clin Electrophysiol 1997;20:938-945.
44. Thomas GP, Ferrier GR, Howlett SE: Losartan exerts antiarrhythmic activity independent of angiotensin II receptor blockade in simulated ventricular ischemia and reperfusion. J Pharmacol Exp Ther 1996;278:1090-1097.
45. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
46. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-1357.
47. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CO, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996;335:1001-1009.
48. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-1307.
49. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-1622.
50. LaRosa JC, He J, Vupputuri S: Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials. JAMA 1999;282:2340-2346.
51. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360:7-22.
52. Dimmeler S, Haendeler J, Galle J, Zeiher AM. Oxidized low-density lipoprotein induces apoptosis of human endothelial cells by activation of CPP32-1ike proteases. A mechanistic clue to the "response to injury" hypothesis. Circulation 1997;95:1760-1763.
53. Hassall DG, Owen JS, Bruckdorfer KR: The aggregation of isolated human platelets in the presence of lipoproteins and prostacyclin. Biochem J 1983;216:43-49.
54. Ridker PM: Evaluating novel cardiovascular risk factors: Can we better predict heart attacks? Ann Intern Med 1999;130:933-937.
55. Seman LJ, McNamara JR, Schaefer EJ: Lipoprotein(a), homocysteine, and remnantlike particles: Emerging risk factors. Curr Opin Cardiol 1999;14:186-191.
56. Ridker PM, Haughie P: Prospective studies of C-reactive protein as a risk factor for cardiovascular disese. J Investig Med 1998;46:391-395.
57. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carries CA, Bauer JA, Tchou PJ, Niebauer MJ, Natale A, Van Wagoner DR: C-reactive protein elevation in patients with atrial arrhythmias: Inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001;104:2886-2891.
58. MacFadyen RJ, Barr CS, Struthers AD: Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997;35:30-34.
59. Duprez DA, De Buyzere ML, Rietzschel ER, Taes Y, Clement DL, Morgan D, Cohn JN: Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 1998;19:1371-1376.
60. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717.
61. Wang W: Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension 1994;24:571-575.
62. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr: Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998;31:451-458.
63. Brown NJ, Nakamura S, Ma L, Nakamura I, Donnert E, Freeman M, Vaughan DE, Fogo AB: Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 2000;58:1219-1227.
64. Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F, Neaton J, Roniker B, Hurley S, Burns D, Bittman R, Kleiman J: The EPHESUS trial: Eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001;15:79-87.
65. Rocha R, Stier CT Jr, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, Adler GK: Aldosterone: A mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000;141:3871-3878.
66. Benetos A, Lacolley P, Safar ME: Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 1997;17:1152-1156.
67. Zannad F, Alla F, Dousset B, Perez A, Pitt B: Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the Randomized Aldactone Evaluation Study (RALES). RALES Investigators. Circulation 2000;102:2700-2706.
68. Stier CT Jr, Chander PN, Rocha R: Aldosterone as a mediator in cardiovascular injury. Cardiol Rev 2002;10:97-107.
69. Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD: Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995;76:1259-1265.
70. Farquharson CA, Struthers AD: Aldosterone induces acute endothelial dysfunction in vivo in humans: Evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond) 2002;103:425-431.
71. Levine SR, Crowley TJ, Hai HA: Hypomagnesemia and ventricular tachycardia: A complication of ulcerative colitis and parenteral hyperalimentation in a nondigitalized noncardiac patient. Chest 1982;81:244-247.
72. Topoi EJ, Lerman BB: Hypomagnesemic torsades de pointes. Am J Cardiol 1983;52:1367-1368.
73. Tsuji H, Venditti FJ Jr, Evans JC, Larson MG, Levy D: The associations of levels of serum potassium and magnesium with ventricular premature complexes (the Framingham Heart Study). Am J Cardiol 1994;74:232-235.
74. Ghani MF, Rabah M: Effect of magnesium chloride on electrical stability of the heart. Am Heart J 1977;94:600-602.
75. Ghani MF, Smith JR: The effectiveness of magnesium chloride in the treatment of ventricular tachyarrhythmias due to digitalis intoxication. Am Heart J 1974;88:621-626.
76. Gottlieb SS, Fisher ML, Pressel MD, Patten RD, Weinberg M, Greenberg N: Effects of intravenous magnesium sulfate on arrhythmias in patients with congestive heart failure. Am Heart J 1993;125:1645-1650.
77. Bashir Y, Sneddon IF, Staunton HA, Haywood GA, Simpson IA, McKenna WJ, Camm AJ: Effects of long-term oral magnesium chloride replacement in congestive heart failure secondary to coronary artery disease. Am J Cardiol 1993;72:1156-1162.
78. Sueta CA, Clarke SW, Dunlap SH, Jensen L, Blauwet MB, Koch G, Patterson JH, Adams KF Jr: Effect of acute magnesium administration on the frequency of ventricular arrhythmia in patients with heart failure. Circulation 1994;89:660-666.
79. Thel MC, Armstrong AL, McNulty SE, Califf RM, O'Connor CM: Randomised trial of magnesium in in-hospital cardiac arrest. Duke Internal Medicine Housestaff. Lancet 1997;350:1272-1276.
80. Antman EM, Lau J, Kupelnick B, Mosteller F, Chalmers TC: A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. JAMA 1992;268:240-248.
81. Teo KK, Yusuf S: Role of magnesium in reducing mortality in acute myocardial infarction. A review of the evidence. Drugs 1993;46:347-359.
82. Woods KL, Fletcher S: Long-term outcome after intravenous magnesium sulphate in suspected acute myocardial infarction: The second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1994;343:816-819.
83. Antman EM: Randomized trials of magnesium in acute myocardial infarction: Big numbers do not tell the whole story. Am J Cardiol 1995;75:391-393.
84. Kimura T, Yasue H, Sakaino N, Rokutanda M, Jougasaki M, Araki H: Effects of magnesium on the tone of isolated human coronary arteries. Comparison with diltiazem and nitroglycerin. Circulation 1989;79:1118-1124.
85. James MF, Beer RE, Esser JD: Intravenous magnesium sulfate inhibits catecholamine release associated with tracheal intubation. Anesth Analg 1989;68:772-776.
86. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994;343:311-322.
87. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988;2:349-360.
88. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet 1986;1:397-402.
89. Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR: Effects of alteplase in acute myocardial infarction: 6-month results from the ASSET study. Anglo-Scandinavian Study of Early Thrombolysis. Lancet 1990;335:1175-1178.
90. A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.). Mortality, morbidity, and infarct size at 21 days. The I.S.A.M. Study Group. N Engl J Med 1986;314:1465-1471.
91. Long-term effects of intravenous anistreplase in acute myocardial infarction: Final report of the AIMS study. AIMS Trial Study Group. Lancet 1990;335:427-431.
92. Collins R, MacMahon S, Flather M, Baigent C, Remvig L, Mortensen S, Appleby P, Godwin J, Yusuf S, Peto R: Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: Systematic overview of randomised trials. BMJ 1996;313:652-659.
93. ISIS-3: A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. Lancet 1992;339:753-770.
94. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993;329:673-682.
95. Cannon CP, McCabe CH, Diver DJ, Herson S, Greene RM, Shah PK, Sequeira RF, Leya F, Kirshenbaum JM, Magorien RD, et al: Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. J Am Coll Cardiol 1994;24:1602-1610.
96. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KA, Premmereur J, Bigonzi F: Low-molecular-weight heparins in non-ST-segment elevation ischemia: The ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events. Am J Cardiol 1998;82:19L-24L.
97. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, Bayes De Luna A, Fox K, Lablanche JM, Radley D, Premmereur J, Braunwald E: Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999;100:1593-1601.
98. Cohen M, Demers C, GurfinkeI EP, Turpie AG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KA, Premmereur J, Bigonzi F: A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997;337:447-452.
99. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med 1998;338:1498-1505.
100. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997;336:1689-1696.
101. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study. Lancet 1997;349:1429-1435.
102. Kong DF, Califf RM, Miller DP, Moliterno DJ, White HD, Harrington RA, Tcheng JE, Lincoff AM, Hasselblad V, Topol EJ: Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998;98:2829-2835.
103. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308:81-106.
104. Granger CB, Califf RM, Topol EJ: Thrombolytic therapy for acute myocardial infarction. A review. Drugs 1992;44:293-325.
105. Anand SS, Yusuf S: Oral anticoagulant therapy in patients with coronary artery disease: A meta-analysis. JAMA 1999;282:2058-2067.
106. van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE: Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): A randomised controlled trial. Lancet 2002;360:109-113.
107. Zipes DP, Wellens HJ: Sudden cardiac death. Circulation 1998;98:2334-2351.
108. Marcus FI, Cobb LA, Edwards JE, Kuller L, Moss AJ, Bigger JT Jr, Fleiss JL, Rolnitzky L, Serokman R: Mechanism of death and prevalence of myocardial ischemic symptoms in the terminal event after acute myocardial infarction. Am J Cardiol 1988;61:8-15.
109. Albert CM, Hennekens CH, O'Donnell CJ, Ajani UA, Carey VJ, Willett WC, Ruskin JN, Manson JE: Fish consumption and risk of sudden cardiac death. JAMA 1998;279:23-28.
110. Siscovick DS, Raghunathan TE, King I, Weinmann S, Wicklund KG, Albright J, Bovbjerg V, Arbogast P, Smith H, Kushi LH, et al: Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA 1995;274:1363-1367.
111. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N: Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: Final report of the Lyon Diet Heart Study. Circulation 1999;99:779-785.
112. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999;354:447-455.
113. Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, Elwood PC, Deadman NM: Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and reinfarction trial (DART). Lancet 1989;2:757-761.
114. Singh RB, Niaz MA, Sharma JP, Kumar R, Rastogi V, Moshiri M: Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: The Indian experiment of infarct survival-4. Cardiovasc Drugs Ther 1997;11:485-491.
115. Christensen JH, Korup E, Aaroe J, Toft E, Moller J, Rasmussen K, Dyerberg J, Schmidt EB: Fish consumption, n-3 fatty acids in cell membranes, and heart rate variability in survivors of myocardial infarction with left ventricular dysfunction. Am J Cardiol 1997;79:1670-1673.
116. Christensen JH, Gustenhoff P, Korup E, Aaroe J, Toft E, Moller J, Rasmussen K, Dyerberg J, Schmidt EB: Effect of fish oil on heart rate variability in survivors of myocardial infarction: A double blind randomised controlled trial. BMJ 1996;312:677-678.
117. Pepe S, McLennan PL: Dietary fish oil confers direct antiarrhythmic properties on the myocardium of rats. J Nutr 1996;126:34-42.
118. Kinoshita I, Itoh K, Nishida-Nakai M, Hirota H, Otsuji S, Shibata N: Antiarrhythmic effects of eicosapentaenoic acid during myocardial infarction-enhanced cardiac microsomal (Ca(2+)-Mg2+)-ATPase activity. Jpn Circ J 1994;58:903-912.
119. Hallaq H, Smith TW, Leaf A: Modulation of dihydropyridine-sensitive calcium channels in heart cells by fish oil fatty acids. Proc Natl Acad Sci USA 1992;89:1760-1764.
120. Grimsgaard S, Bonaa KH, Hansen JB, Myhre ES: Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on hemodynamics in humans. Am J Clin Nutr 1998;68:52-59.
121. Kang JX, Leaf A: Antiarrhythmic effects of polyunsaturated fatty acids. Recent studies. Circulation 1996;94:1774-1780.
122. Kris-Etherton PM, Harris WS, Appel LJ: Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002;106:2747-2757.